CD19 and precursor B-cell acute lymphoblastic leukemia: Approximately 30% of pediatric and young adult B-ALL patients treated with anti-CD19 CAR T cells relapse with a CD19-negative disease (21), and CD19 loss and downregulation has been observed in the NHL setting as well (84).